Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hepatitis A vaccine (inactivated, adsorbed)
Hepatitis A vaccine · 1 trial · 1 indication
The seroconversion rate of anti-hepatitis A virus (HAV) antibodies 30 days after the second vaccination
| Arm | Type | Description |
|---|---|---|
| Adult dose, treatment group (≥16 years) | EXPERIMENTAL | - |
| Pediatric dose, treatment group (6~ <16 years) | EXPERIMENTAL | - |
| Pediatric dose, control group (6~ <16 years) | ACTIVE_COMPARATOR | - |
| Pediatric dose, treatment group (1~ <6 years) | EXPERIMENTAL | - |
| Pediatric dose, conrol group (1~ <6 years) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL) | BIOLOGICAL | Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, adult dose (≥ 16 years) |
| Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL) | BIOLOGICAL | Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, pediatric dose (1\~\<16 years) |
| Hepatitis A vaccine (inactivated, adsorbed) | BIOLOGICAL | Hepatitis A vaccine (inactivated, adsorbed) manufactured by Sanofi |
Inclusion Criteria: 1. Healthy participants aged 1 year and older; 2. Participants (and/or their legal guardians) are able to understand and sign the informed consent voluntarily; 3. Participants of reproductive potential and their sexual partners should voluntarily use effective contraception from...
Hepatitis A vaccine is used for the prevention of Hepatitis A infection. It is an inactivated, adsorbed vaccine being developed for use in individuals as young as 1 year old. The vaccine is intended to stimulate the immune system to produce protection against the Hepatitis A virus.
Hepatitis A vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company. The company is conducting a Phase 3 clinical trial for this vaccine candidate. Sinovac Biotech is listed on the stock exchange under the ticker symbol SVA.
Hepatitis A vaccine is currently in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved for public use. The Phase 3 trial is actively recruiting participants to evaluate the vaccine's safety and efficacy in preventing Hepatitis A.
Hepatitis A vaccine is being studied in a Phase 3 clinical trial with the identifier NCT07793227. This trial is titled 'Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine' and is currently recruiting participants in Vietnam. The study is randomized, double-blind, and active-controlled, with an enrollment target of 680 participants.
Yes, Hepatitis A vaccine is also known as Hepatitis A vaccine (inactivated, adsorbed). This alternative name describes the vaccine's formulation, which contains inactivated Hepatitis A virus particles that are adsorbed to an adjuvant to enhance the immune response.